IR-MED Overview
IR-MED is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company’s AI process to provide healthcare professionals with decision support in the detection and monitoring of various disease conditions. PressureSafe, the company’s first product based on this platform, is a handheld device designed to revolutionize early detection of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually. PressureSafe is expected to contribute to early detection of pressure injuries, regardless of patient skin tone. This will drive equitable healthcare and help reduce the toll and cost of PI. IR-MED holds patents protecting its innovation in noninvasive tissue analysis and in modeling and analysis of subcutaneous tissue.
Cumulative Funding Raised Over Time ($)
$1.0M
$4.2MApr 2022
Latest News
growth-positive
IR-MED's Key Clinical and Media Milestones
IR-Med Inc., a medical technology company, is gaining visibility in the healthcare and investment communities through recent milestones. The company presented its AI-powered infrared spectroscopy platform, PressureSafe™, at the Magnet & Pathway 2025 Conference, showcasing its effectiveness in assessing pressure injuries across diverse skin tones. This presentation, along with a feature on Israels Channel 10 and participation in the National Investment Banking Association Conference, highlights IR-Meds progress towards commercialization and its potential impact on non-invasive skin assessment. These activities have broadened the companys exposure and are part of a strategic push to engage with the U.S. investment community and national media.
Product StageInvestment
growth-positive
IR-MED Investor Update Letter - Sept-2025
IR-MED Inc., a developer of AI-powered spectrographic technology, has made significant strides towards commercialization. The companys PressureSafe™ device is now FDA-listed, allowing entry into the U.S. market. Additionally, IR-MED received a $500K grant from the Israel Innovation Authority to support the clinical advancement of DiaSafe™, an AI-powered diagnostic device for diabetic foot ulcers. The company is conducting a usability study at HCA Methodist Healthcare in Texas, achieving promising results. However, further funding is needed to continue operations and strategic initiatives.
Product StageInvestment
growth-positive
IR-MED Reports Positive Interim Results from U.S. Clinical Study of PressureSafe(TM) for Pressure Injury Assessment Across Diverse Skin Tones
IR-MED Inc., a developer of AI-powered spectrographic technology, announced positive interim results from its U.S. clinical study of PressureSafe™, a device for assessing pressure injuries before visible skin breakdown. The study, conducted at Methodist Healthcare in San Antonio, Texas, demonstrated a 94% sensitivity in assessing tissue at risk for pressure injuries, particularly benefiting patients with darker skin tones. These findings were presented at the HCA Healthcare & Galen College of Nursing Research Day and will be featured at the 2025 ANCC Magnet/ANE Research Symposium. The results highlight PressureSafes potential to improve equity and patient outcomes in pressure injury prevention.
Product StageCustomers
growth-positive
IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment
IR-MED Inc., a developer of AI-driven spectrographic technology, has received a $500,000 grant from the Israel Innovation Authority to support the development of its DiaSafe™ device. This device aims to provide real-time optical readings of biomarkers for assessing diabetic foot ulcers, a condition that can lead to amputations if not treated early. The grant will fund 40% of a $1.24 million budget for the next development stage, including the initiation of the first in-human clinical trial. The DiaSafe™ device is designed to improve patient care and reduce healthcare costs by enabling early assessment of diabetic foot ulcers.
Product StageInvestment
growth-positive
IR-MED CEO Issues Letter to Shareholders: Expanding Our Platform and Presenting New Clinical Data from Israel and the U.S.
IR-Med, Inc., a developer of AI-driven spectrographic analysis technology, is expanding the usability studies of its PressureSafe™ device in the U.S. The device addresses a significant healthcare need by assessing pressure injuries, with a market potential of $1.7 billion domestically and $2.9 billion globally. Recent studies in Israel and the U.S. have shown promising results, with high sensitivity and specificity rates. The company demonstrated its technology at the National Pressure Injury Advisory Panel 2025 Conference, attracting interest from healthcare professionals and commercial partners. The ongoing studies aim to enhance the assessment of pressure injuries and reduce reliance on subjective visual assessments.
Product StageCustomers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $8.73M |
| Last funding | $500K |
| Stage | Public |
| Rounds | 5 |
| Investors | 1 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | www.ir-medical.com |
Locations
Rosh Pinna, Israel
Photos & Videos
1 item(s)
IR-MED Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesDiagnostics DevicesTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
SensingOpticInfraredArtificial IntelligenceMachine LearningTags (21)
non-invasivemedical-technologiespharma-companiespatent-pendingclinicshealthcare-providerspharmaceuticalsmedical-devicesearly-detectionmonitoringhospitalsinfraredsensorsartificial-intelligencedigital-healthcaremachine-learningchildrendiagnosticsopticsremote-monitoringulcersGeographic Markets
United StatesIndiaEuropeIsraelChinaIR-MED Financials
$8.73M
Total funding
Undisclosed
Capital raised
$500K
Last funding
Public
Funding stage
5
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
$1.0M
$4.2MApr 2022
Private Equity Funding
PIPE
Apr 2022
$3.2M
Undisclosed Investor(s)
Seed
$1M
Non-Equity Funding
GrantEvent
May 2025
$500K
Israel Innovation Authority (Lead)
GrantEvent
Jul 2024
$500K
Israel Innovation Authority (Lead)
Public Offering / Exit
POEvent
Jan 2021
Undisclosed
ReverseMergerEvent
Dec 2020
Undisclosed
IR-MED Lifecycle
Cumulative Funding Raised Over Time
$1.0M
$4.2MApr 2022
All Events
PIPE
Apr 2022
$3.2M
Undisclosed Investor(s)
Seed
$1M
GrantEvent
May 2025
$500K
Israel Innovation Authority (Lead)
GrantEvent
Jul 2024
$500K
Israel Innovation Authority (Lead)
POEvent
Jan 2021
Undisclosed
ReverseMergerEvent
Dec 2020
Undisclosed
IR-MED News
52 articles
growth-positive
IR-MED's Key Clinical and Media Milestones
IR-Med Inc., a medical technology company, is gaining visibility in the healthcare and investment communities through recent milestones. The company presented its AI-powered infrared spectroscopy platform, PressureSafe™, at the Magnet & Pathway 2025 Conference, showcasing its effectiveness in assessing pressure injuries across diverse skin tones. This presentation, along with a feature on Israels Channel 10 and participation in the National Investment Banking Association Conference, highlights IR-Meds progress towards commercialization and its potential impact on non-invasive skin assessment. These activities have broadened the companys exposure and are part of a strategic push to engage with the U.S. investment community and national media.
Product StageInvestment
growth-positive
IR-MED Investor Update Letter - Sept-2025
IR-MED Inc., a developer of AI-powered spectrographic technology, has made significant strides towards commercialization. The companys PressureSafe™ device is now FDA-listed, allowing entry into the U.S. market. Additionally, IR-MED received a $500K grant from the Israel Innovation Authority to support the clinical advancement of DiaSafe™, an AI-powered diagnostic device for diabetic foot ulcers. The company is conducting a usability study at HCA Methodist Healthcare in Texas, achieving promising results. However, further funding is needed to continue operations and strategic initiatives.
Product StageInvestment
growth-positive
IR-MED Reports Positive Interim Results from U.S. Clinical Study of PressureSafe(TM) for Pressure Injury Assessment Across Diverse Skin Tones
IR-MED Inc., a developer of AI-powered spectrographic technology, announced positive interim results from its U.S. clinical study of PressureSafe™, a device for assessing pressure injuries before visible skin breakdown. The study, conducted at Methodist Healthcare in San Antonio, Texas, demonstrated a 94% sensitivity in assessing tissue at risk for pressure injuries, particularly benefiting patients with darker skin tones. These findings were presented at the HCA Healthcare & Galen College of Nursing Research Day and will be featured at the 2025 ANCC Magnet/ANE Research Symposium. The results highlight PressureSafes potential to improve equity and patient outcomes in pressure injury prevention.
Product StageCustomers
growth-positive
IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment
IR-MED Inc., a developer of AI-driven spectrographic technology, has received a $500,000 grant from the Israel Innovation Authority to support the development of its DiaSafe™ device. This device aims to provide real-time optical readings of biomarkers for assessing diabetic foot ulcers, a condition that can lead to amputations if not treated early. The grant will fund 40% of a $1.24 million budget for the next development stage, including the initiation of the first in-human clinical trial. The DiaSafe™ device is designed to improve patient care and reduce healthcare costs by enabling early assessment of diabetic foot ulcers.
Product StageInvestment
growth-positive
IR-MED CEO Issues Letter to Shareholders: Expanding Our Platform and Presenting New Clinical Data from Israel and the U.S.
IR-Med, Inc., a developer of AI-driven spectrographic analysis technology, is expanding the usability studies of its PressureSafe™ device in the U.S. The device addresses a significant healthcare need by assessing pressure injuries, with a market potential of $1.7 billion domestically and $2.9 billion globally. Recent studies in Israel and the U.S. have shown promising results, with high sensitivity and specificity rates. The company demonstrated its technology at the National Pressure Injury Advisory Panel 2025 Conference, attracting interest from healthcare professionals and commercial partners. The ongoing studies aim to enhance the assessment of pressure injuries and reduce reliance on subjective visual assessments.
Product StageCustomers
growth-positive
Methodist Healthcare Adopts IR-MED’s PressureSafe™ Device for Usability Study: Decision Support Device Aims to Reduce Substantial Healthcare Burden of Pressure Injuries
IR-Med, Inc. has commenced a usability study for its PressureSafe™ device at Methodist Healthcare in San Antonio, Texas. The study aims to improve early detection and prevention of pressure injuries, particularly in individuals with darker skin tones. PressureSafe™ uses AI and infrared light to detect biomarkers beneath the skins surface. The study will enroll up to 104 participants and is expected to enhance patient outcomes and reduce healthcare costs. Previous studies showed a 92% detection efficacy and a 50% reduction in pressure injuries. Methodist Healthcare is a key partner in this initiative.
CustomersPartners
growth-positive
IR-MED Appoints Ran Ziskind, Tech Entrepreneur, Growth Manager, and Inventor as Chief Executive Officer
IR-MED Inc., a developer of noninvasive AI-driven spectrographic analysis technology, announced the appointment of Ran Ziskind as the new Chief Executive Officer, effective September 1, 2024. Ziskind, a seasoned tech entrepreneur with extensive experience in launching and expanding innovative enterprises, is expected to lead IR-MED into a growth phase. The company is preparing to launch its first product, PressureSafe™, a handheld device for early detection of pressure injuries. The appointment is seen as a strategic move to leverage Ziskinds expertise in commercializing medical technologies and driving market share.
Management Changes
growth-positive
IR-MED Wins Prestigious Netty Award for Best Up-and-Coming Health Tech Company
IR-MED Inc., a developer of a noninvasive AI-driven spectrographic analysis technology platform, has been awarded the Best Up-and-Coming Health Tech Company at the Netty Awards. The companys technology is designed to improve patient care by providing healthcare professionals with non-invasive, real-time data-driven analysis of blood and tissue to identify medical conditions. The companys PressureSafe device, which identifies early-stage pressure injuries with 92% accuracy, is set to launch in the U.S. in the second half of 2024. DiaSafe, a similar device for diabetic foot ulcer detection, is slated for launch in the U.S. in the second half of 2025.
CustomersExpand
growth-positive
IRME: IR-Med’s Potential for Profitable Growth in Future Years Supports Price Target of $3.00.
IR-Med released its Q2 2024 financial results, which were largely in line with expectations. The company recorded no revenues for the quarter, but R&D expenses decreased to $94,000 from $496,000 in Q2 2023. The company also received a support plan of approximately $1 million from the Israeli Innovation Authority. IR-Meds PressureSafe device received FDA listing for the indication of pressure injuries. The company expects to commence usability studies in the U.S. in 2024. The global market for Pressure Injury solutions is estimated to be $600 million in the U.S. and $2.9 billion globally.
Investment
growth-positive
IR-MED Receives $500,000 Grant from the Israel Innovation Authority to Develop its Platform Technology for the Early Detection of Diabetic Foot Ulcers
IR-MED Inc., a developer of noninvasive artificial intelligence-driven spectrographic analysis technology, has received a grant of approximately $500,000 from the Israel Innovation Authority (IIA). The grant is to develop its platform technology for a new indication, a decision support device for the early detection of diabetic foot ulcers. The development timeline is proceeding on schedule, with the company currently building the DiaSafe devices hardware. The device is designed to non-invasively analyze the biomarkers of blood and tissue to help healthcare providers prevent diabetic foot ulcers from developing in their diabetic patients.
Investment
growth-positive
IR-MED’s PressureSafe device cuts pressure injury incidence by half
Israel-based IR-MED has announced positive results from the usability study of its pressure injury detection device, PressureSafe. The device uses AI to analyse the infrared spectrographic data collected by the device to detect the presence of pressure injuries. It received a listing as a Class I decision support device from the US Food and Drug Administration (FDA) last month. The usability study was carried out in Israel at two medical centres owned by Clalit. The device demonstrated 92% sensitivity and 88% specificity in detecting suspected or Stage I deep tissue injury (sDTI) pressure injuries.
InvestmentCustomers
growth-positive
IR-MED’s PressureSafe™ Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel’s Largest HMO
IR-MED Inc., a developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform, has published a poster presentation on its website detailing the results of a clinical study on its product, PressureSafe™. The study, conducted in partnership with two medical centers owned by Clalit, the world’s second largest health maintenance organization (HMO), showed that PressureSafe™ detected Stage 1 / suspected deep tissue injury (sDTI) pressure injuries with 92% sensitivity and 88% specificity. The incidences of pressure injuries were reduced by 50% during the study period. PressureSafe™ has received U.S. Food and Drug Administration (FDA) listing confirmation for the indication of pressure injuries.
CustomersPartners
growth-positive
IRME: IR-Med Announces 1st Quarter 2024 Financial and Operating Results
IR-Med released its 10-Q filing for the first quarter of 2024, showing a decrease in expenses and a net loss of $657,000. The company received a $1 million support plan from the Israeli innovation authority, half of which is a grant. IR-Med has narrowed its product development focus due to limited financial resources, concentrating on the development of decision support system solutions for the diagnosis of pressure injuries and diabetic foot ulcers. The companys PressureSafe device received FDA approval in April 2024. IR-Med plans to commence usability studies in the U.S. in 2024.
Investment
Growth-Positive
IRME: IR-Med’s Potential for Profitable Growth in Coming Years Supports Price Target of $3.00.
IR-Med (OTC:IRME) released its annual 10-K filing on April 1, 2024, with no revenues in 2023 and increased research and development expenses. The company raised $1.0 million in proceeds in 2023 from the sale of common stock and warrants. The Israeli innovation authority approved a support plan of approximately $1.0 million for the company. On April 5, 2024, the company announced that its PressureSafe decision support device received U.S. FDA listing for the indication of pressure injuries. The company plans to start a usability study for PressureSafe in the U.S. in collaboration with Methodist Healthcare of San Antonio.
Investment
Growth-Positive
IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries
IR-MED Inc., a developer of noninvasive artificial intelligence (AI) driven spectrographic analysis technology, has announced that its PressureSafe™ decision support device has received U.S. Food and Drug Administration (FDA) listing for the indication of pressure injuries. The device uses infra-red spectroscopy combined with an AI-based algorithm for the early, non-invasive, and skin color agnostic detection of pressure injuries. The company plans to expand its usability studies into the U.S. and expects to commence with a major hospital network in 2024.
CustomersPartnersExpand
growth-positive
IRME: IR-Med’s positive safety and efficacy data from recent PressureSafe study supports price target of $3.00.
On February 20, 2024, IR-Med announced positive efficacy data for PressureSafe, a device that uses infra-red spectroscopy and an AI-based algorithm for early detection of pressure injuries. The data was collected at two medical centers owned by Clalit, the largest health maintenance organization in Israel. The study found that PressureSafe detected Stage 1 pressure injuries with 92% sensitivity and 88% specificity. The company plans to start a usability study for PressureSafe in the U.S. in collaboration with Methodist Healthcare of San Antonio. IR-Meds CEO, Tzur Di-Cori, believes the positive findings will drive adoption in the U.S.
PartnersCustomers
growth-positive
IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries
IR-Med, Inc. has reported positive data for PressureSafe, its AI-driven device for early detection of pressure injuries. The study, conducted at two medical centers owned by Clalit, the worlds second-largest HMO, showed that PressureSafe detected early-stage pressure injuries with 92% sensitivity and 88% specificity. The device uses infrared spectroscopy combined with an AI-based algorithm for non-invasive detection of pressure injuries. During the study period, the incidence of pressure injuries was reduced by approximately 50%. The company plans to enter the U.S. market with PressureSafe and start a usability study in collaboration with Methodist Healthcare of San Antonio.
CustomersPartnersExpand
growth-positive
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16
IR-Med, Inc. has announced the final data from a study conducted at two medical centers owned by Clalit, the worlds second largest health maintenance organization (HMO) and the largest in Israel. The study evaluated the safety and efficacy of PressureSafe, IR-Meds decision support device that uses infra-red spectroscopy combined with an AI-based algorithm to diagnose Stage 1 pressure injuries. The results will be presented at the National Pressure Injury Advisory Panel (NPIAP) 2024 Annual Conference. The device has the potential to significantly reduce the incidence of pressure injuries and corresponding human suffering and medical costs.
CustomersPartners
growth-positive
IR-MED Awarded Most Innovative Non-Invasive Diagnostics Technology Developer 2023 by Corporate Vision Magazine
IR-Med Inc., a developer of noninvasive AI-driven spectrographic analysis technology, has been awarded the Most Innovative Non-Invasive Diagnostics Technology Developer 2023 – Israel by Corporate Vision Magazine. The award recognizes the companys PressureSafe device, a non-invasive medical device that uses infrared optical spectroscopy and AI to detect early-stage pressure injuries. The device is expected to launch in the U.S. in the first half of 2024, subject to regulatory approval. Pressure injuries cost the U.S. healthcare system $26.8 billion and lead to 60,000 deaths annually.
CustomersExpand
growth-positive
IR-MED Awarded Most Innovative Non-Invasive Diagnostics Technology Developer 2023 by Corporate Vision Magazine
IR-MED Inc., a developer of non-invasive diagnostics technology, has been recognized as the Most Innovative Non-Invasive Diagnostics Technology Developer 2023 by Corporate Vision Magazine for its PressureSafe device. This device, which uses AI-driven spectrographic analysis, is designed to detect early-stage pressure injuries with over 90% accuracy. Pressure injuries are a significant healthcare challenge in the U.S., costing $26.8 billion and causing 60,000 deaths annually. The PressureSafe device is expected to launch in the U.S. in 2024, pending regulatory approval. This recognition highlights IR-MEDs contribution to healthcare innovation and its potential impact on reducing pressure injuries.
growth-positive
IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue
IR-MED Inc., a developer of noninvasive AI-driven spectrographic analysis technology, has been granted a patent for its platform technology by the State of Israel Patent Office. This follows a similar patent granted in the U.S. The patent covers IR-MEDs PressureSafe™ decision support device for early detection of pressure injuries. The device is set to launch in the U.S. in the first half of 2024. The companys CEO, Tzur Di-Cori, believes that the patent will add significant value as they near the commercial launch of PressureSafe™ in the U.S.
InvestmentExpand
growth-positive
IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue
IR-Med, Inc., a developer of noninvasive AI-driven spectrographic analysis technology, announced it has been granted a patent from the State of Israel Patent Office for its PressureSafe™ decision support device. This patent follows a similar one granted in the U.S., with other applications pending in key markets like the European Union. PressureSafe™ is designed to detect early-stage pressure injuries with over 90% accuracy, addressing a significant healthcare burden in the U.S. The device is slated for launch in the U.S. in the first half of 2024. The patent enhances IR-MEDs portfolio, adding value as the company approaches the commercial launch of PressureSafe™. The device aims to improve health outcomes and reduce costs associated with advanced-stage pressure injuries.
Neutral
IRME: IR-MED reports 3rd quarter financial results which were in line with expectations.
IR-MED reported its 3rd quarter financial results for 2023, with no revenues recorded as the companys products are still in development. R&D expenses were $469,000, similar to the previous year, while marketing expenses increased to $297,000 from $24,000 in the 3rd quarter of 2022. General and administrative expenses also increased to $431,000 from $384,000 in the prior year. The company reported a net loss of $1.18 million for the quarter. On October 15, 2023, the company hired a new CEO, Mr. Tzur Di-Cori. Additionally, the company signed a Clinical Trial Agreement with the Methodist Healthcare System of San Antonio on September 26, 2023.
Management ChangesPartners
growth-positive
IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer
IR-MED Inc. announced the appointment of Tzur Di-Cori as the new Chief Executive Officer, effective October 15, 2023. Di-Cori brings over 30 years of experience in the healthcare and technology sectors, having held executive roles in various successful companies. His expertise is expected to propel IR-MED as it prepares for the commercial launch of its PressureSafe™ device in the U.S., pending regulatory approval. PressureSafe is a noninvasive device designed to detect pressure injuries early, potentially improving patient care and healthcare economics. The company is optimistic about the future under Di-Coris leadership, as his experience aligns with IR-MEDs mission to innovate in healthcare technology.
Management Changes
growth-positive
IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer
IR-MED Inc., a developer of noninvasive AI-driven spectrographic analysis technology, has announced that Tzur Di-Cori will join the company as CEO from October 15, 2023. Di-Cori brings over 30 years of experience in executive positions at several successful medical device and high-tech companies. The company is preparing for the commercial launch of PressureSafe in the U.S., pending regulatory approval, which is expected in the current fiscal quarter.
Management Changes
growth-positive
IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024
IR-MED Inc., a developer of noninvasive artificial intelligence (AI) driven spectrographic analysis technology, has signed a Clinical Trial Agreement with the Methodist Healthcare System of San Antonio to conduct a usability study of its PressureSafe device. The device uses AI and infrared light to detect early-stage pressure injuries in people of various skin tones, including dark skin tones. The study aims to address healthcare inequality in the early detection of pressure injuries. Interim results from a previous study in Israel indicate that PressureSafe identified early-stage pressure injuries with 96% accuracy. The company plans to launch the product in the first half of 2024, following regulatory filings.
PartnersExpand
growth-positive
IR-MED Appoints Richard Serbin, Esq. to its Advisory Board
IR-Med, Inc., a developer of noninvasive AI-driven spectrographic analysis technology, announced the appointment of Richard Serbin to its Advisory Board. Serbin brings extensive experience in FDA regulatory matters, patent counsel, and business development. His appointment is seen as a strategic move as IR-Med prepares to file for FDA approval for its PressureSafe™ device, aimed at early detection of pressure injuries. The company is optimistic about the potential market launch of PressureSafe in the U.S. and its impact on healthcare outcomes and cost savings. The announcement is a positive development for IR-Med as it strengthens its leadership team and moves closer to commercializing its innovative healthcare solutions.
Management Changes
growth-positive
IRME: Initiating coverage of IR-Med, Inc., a development stage medical device company that is creating a technology platform for non-invasive devices to be used as a decision support system tool (DSS).
IR-Med, Inc. is a development stage medical device company that is creating a technology platform for non-invasive devices to be used as a decision support system tool for various medical indications. Their initial product, PressureSafe, is a handheld optical monitoring device for early detection of pressure injuries. They are also developing an otoscope called Nobiotics for diagnosing mid-ear infections. The company plans to launch these devices as decision support system tools for caregivers in healthcare settings. They utilize artificial intelligence in their technology platform and have a focus on pre-emptive diagnosis. The company uplisted to the OTCQB market tier in February 2022 and aims to uplist to the national market in the future. They had $2.3 million in cash and $1.8 million in working capital as of June 30, 2023. The global market for Pressure Injury solutions is estimated to be $600 million in the U.S. and $2.9 billion globally.
Customers
growth-positive
IR-MED Chairman & Interim CEO Issues Letter to Shareholders
IR-Med, Inc. plans to uplist its common stock to a major exchange in the U.S. The company is developing a noninvasive AI-driven infrared spectrographic analysis technology platform. They are currently working on their first product, PressureSafe, which is a handheld optical monitoring device for early detection of pressure injuries. The company plans to list PressureSafe with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2023 and launch it in the U.S. in the first half of 2024. The market opportunity for PressureSafe is estimated to be $600 million in the U.S. and $2.9 billion globally. The company also plans to file for regulatory approval and launch PressureSafe in other markets. They are building a portfolio of products to address significant healthcare needs.
Public TradingCustomersExpand
growth-positive
IR-MED’s AI-Powered Infra-Red Spectrographic Decision Support System PressureSafe Device Demonstrates High Efficacy in Detecting Pressure Injuries with 96% Accuracy: Potential to Set a New Standard of Care
IR-MED Inc., a developer of noninvasive AI-driven Infra-Red spectrographic analysis technology, announced positive interim results from a clinical study of PressureSafe, a device for early detection of pressure injuries. The study, conducted at two medical centers owned by Clalit, showed a high efficacy in detecting pressure injuries below the skin’s surface. The company plans to file for U.S. FDA approval in Q4 2023 and expects a U.S. market launch in H1 2024. PressureSafe could become the new standard of care in the detection of pressure injuries, improving patient outcomes and contributing to healthcare provider’s data-driven decision making.
InvestmentExpand
growth-positive
IR-MED Honors Juneteenth with Commitment to Healthcare Equality: PressureSafe Device Sees Beneath the Skin to Address Inequality in Pressure Injuries
IR-Med, Inc. is committed to addressing healthcare inequality with its non-invasive AI-driven spectrographic analysis technology platform. The companys breakthrough product, PressureSafe, is a non-invasive medical device that uses infrared optical spectroscopy and AI to detect early-stage pressure injuries for all skin tones. This is particularly important for minority populations, as a 5-year study found that people with dark skin tones are more than twice as likely to suffer from pressure injuries. PressureSafe is expected to launch in the U.S. in the first quarter of 2024. Dr. David Dalton, a visionary healthcare thought leader, is supporting IR-Med in analyzing the benefits of the device for African American and Hispanic populations. The companys goal is to improve patient care and healthcare equality.
Customers
growth-positive
IR-Med Appoints Dr. Lynn Eschenbacher to its Advisory Board as Company Advances Toward Launch of its PressureSafe Wound Care Device
IR-MED Inc., a developer of non-invasive AI-driven spectrographic analysis technology, has appointed Dr. Lynn Eschenbacher to its Advisory Board. Dr. Eschenbacher will advise on the development and market launch of the companys lead product, PressureSafe, which uses infrared light to detect pressure injuries. The company plans to file for regulatory approval in Q4 2023. IR-MED estimates an addressable market of over 200 million tests for PressureSafe annually. The appointment of Dr. Eschenbacher is expected to have a positive impact on the companys growth. The article discusses the importance of early detection of pressure injuries and the potential impact of PressureSafe in reducing mortality and healthcare costs. The article does not mention any specific partners, investors, customers, or financial figures.
PartnersInvestment
growth-positive
IR-Med’s PressureSafe Noninvasive Wound Care Device to be Demonstrated at Northwell Health’s 10th Annual Shining the Light on Wound Care Symposium
IR-Med, Inc. will exhibit and conduct live demonstrations of its PressureSafe wound care device at Northwell Health’s 10th Annual Shining the Light on Wound Care Symposium. PressureSafe is a noninvasive AI-driven spectrographic analysis technology platform that can accurately detect and identify Stage 1 pressure injuries. The device uses penetrating infrared light to sense biomarkers and structural changes in tissue layers, providing clinical feedback as a decision support system. The company aims to build awareness around the device and believes it is a breakthrough in early detection of pressure wounds, particularly for minority populations. Early detection can improve patient wellness, reduce costs, and decrease mortality. IR-Med is developing a handheld optical monitoring device that calibrates to each patients skin and is expected to launch in the US in the fourth quarter of 2023, pending regulatory approval.
Customers
IR-Med to present at National Pressure Injury Advisory Panel 2023
IR-MED SIGNS AGREEMENT TO EXPAND ITS PRESSURESAFE DEVICE USABILITY STUDY
IR-Med Gains Momentum in 2022
IR-Med Announces Dr. David Dalton as Advisory Board member
IR-Med Signs Agreement for the Commercial Design of the PressureSafe Device
growth-positive
IR-Med Signs Agreement for the Commercial Design of the PressureSafe Device
IR-Med, Inc., a medical device company, has announced that its subsidiary IR-Med Ltd. has signed an agreement with Bina Industrial Design Ltd. for the commercial design of the PressureSafe device. The device is being developed for the detection and classification of early-stage pressure injuries. The agreement covers the design of the device in its advanced configuration, incorporating feedback from a usability study. Bina Industrial Design specializes in the design of medical devices and serves multinational companies. The PressureSafe device utilizes spectrographic analysis, proprietary technologies, and AI capabilities for early detection of pressure injuries. Pressure injuries are a major challenge for healthcare providers, with significant costs and potential fatalities. The partnership with Bina Industrial Design is expected to advance the development of the device.
Partners
growth-positive
IR-Med files Provisional Patent Application Covering Additional Features of its PressureSafe Device for Early Detection of Pressure Injuries
IR-Med, Inc., a medical device company, has announced that its subsidiary has submitted a provisional patent application for its non-invasive device, PressureSafe, which detects and classifies early-stage pressure injuries. The device combines several technologies to obtain real-time high accuracy data related to pressure injuries. Pressure injuries are a major challenge for care providers, and failure to identify and treat them can be fatal. The provisional patent application aims to protect the intellectual property generated during the devices development. The device has the potential to provide accurate and real-time information for early detection and treatment of pressure injuries. IR-Med, Inc. is developing a non-invasive spectrographic analysis technology platform for healthcare professionals to detect and measure molecules in the blood and human tissue without invasive procedures.
Investment
growth-positive
IR-Med files Provisional Patent Application Covering Additional Features of its PressureSafe Device for Early Detection of Pressure Injuries
IR-Med, Inc., an Israeli medical device company, has announced that its subsidiary IR-Med Ltd. has submitted a new provisional patent application for its non-invasive device, PressureSafe, which detects and classifies early-stage pressure injuries. The device, currently in development, uses Infra-Red light spectroscopy and Artificial Intelligence to provide real-time, high-accuracy data. The patent application covers advanced methods that combine several technologies. Pressure injuries are a significant challenge for care providers worldwide, with an estimated 60,000 mortalities from such injuries in the US each year. The PressureSafe device could potentially provide accurate and real-time information, aiding in early detection and treatment.
InvestmentExpand
growth-positive
IR-Med To Initiate Useability Study of its PressureSafe Device
IR-Med, Inc., an innovative medical device company, has announced a study agreement with Beit Rivka, a large geriatric hospital in Israel. The agreement is to conduct a usability study of IR-Meds proprietary and patent-protected Pressuresafe device, which uses AI technologies for the early detection of pressure injuries to the skin and underlying tissue. The device is expected to be launched as a decision support system tool for caregivers in hospitals, nursing homes, and home-care companies. Pressure injuries are a major challenge for care providers worldwide, with an estimated 60,000 mortalities from such injuries in the US each year.
PartnersExpand
growth-positive
IR-Med To Initiate Useability Study of its PressureSafe Device
IR-MED, a medical device company, has signed a study agreement with Beit Rivka, a Large Geriatric Hospital in Israel, to conduct a usability study of its proprietary and patent-protected Pressuresafe device. The device utilizes AI technologies to detect pressure injuries to the skin and underlying tissue. Pressure injuries are a major challenge for care providers, with an estimated 60,000 mortalities from pressure injuries in the US each year. The study aims to provide accurate and real-time information to caregivers, potentially preventing the development of pressure injuries. The devices ability to detect pressure injuries regardless of different skin colors and inform caregivers before any visible signs can be seen holds promise for better patient compliance and quality of life. IR-MED is developing a non-invasive spectrographic analysis technology platform for healthcare professionals.
PartnersCustomers
IR-MED Names Moshe Gerber as New CEO
IR-Med Announces $3.2 Million Private Placement
growth-positive
IR-Med to Become Fully Reporting SEC Company
IR-Med, Inc. has filed an application to uplist to the OTCQB market tier. The companys resale Registration Statement on Form S-1 has been declared effective by the SEC. IR-Med is not selling any securities under the Registration Statement, but it allows for the potential resale of securities by certain security holders. The company has also initiated a strategy to increase its visibility and upgrade its position in the public markets. IR-Med is led by CEO Rom Eliaz and is developing non-invasive spectrographic analysis technology for healthcare professionals. Their first product under development is a handheld optical monitoring device for early detection of pressure injuries. The company holds patents in noninvasive tissue analysis and is in the process of examining additional patent applications.
Public Trading
growth-negative
IR-Med, Inc. Announces the Resignation of Limor Davidson Mund as CEO and Appointment of Chairman of the Board Oded Bashan as Interim Chief Executive Officer
IR-Med, Inc announced the resignation of Limor Davidson Mund as Chief Executive Officer. Mr. Oded Bashan, the Companys Chairman, has been appointed Chief Executive Officer on an interim basis. IR-Med is a development stage company focused on the development and application of Infra-Red and Artificial Intelligence technologies for medical ailments.
Management Changes
growth-positive
IR-Med, Inc. Announces FINRA Approval of Name Change and Ticker Symbol Change to "IRME"
IR-Med, Inc has announced a name change to IR Med, Inc and a ticker symbol change to IRME. These changes follow the successful completion of a share exchange transaction with I.R Med Ltd, making it a wholly-owned subsidiary of the company. The CEO stated that the changes represent a deliberate and strategic rebranding effort. IR-Med is a development stage company focused on the development and application of Infra-Red (IR) and Artificial Intelligence (AI) technologies for medical ailments, particularly the early detection of pressure injuries and ear infection diagnosis in children.
Public Trading
growth-positive
INTERNATIONAL DISPLAY ADVERTISING, INC. ANNOUNCES COMPLETION OF REVERSE MERGER AND CLOSING OF $2.2 MILLION PRIVATE PLACEMENT
International Display Advertising, Inc. has completed a share exchange transaction with I.R Med Ltd., making it a wholly-owned subsidiary of the company. The combined entity will focus on the development of Infra-Red and Artificial Intelligence technologies for medical diagnosis. The company has also closed a private placement, raising approximately $2.2 million in gross proceeds. The funds will be used to advance the companys product portfolio and for general corporate purposes. The company plans to change its corporate name to IR-Med, Inc. and has applied for approval from the Financial Industry Regulatory Authority (FINRA). Limor Davidson Mund has been appointed as the new CEO. The company will file a registration statement to cover the resale of the shares issued in the private placement. The Board of Directors now consists of Yoram Drucker, David Lazar, Oded Bashan, Ohad Bashan, Aharon Klein, Ron Mayron, and Yaniv Cohen.
AcquisitionInvestment
growth-positive
INTERNATIONAL DISPLAY ADVERTISING, INC AND IR MED LTD EXTEND OUTSIDE DATE OF SECURITIES EXCHANGE AGREEMENT
International Display Advertising, Inc. (IDAD) has announced an extension of the outside date for the acquisition of IR Med Ltd. The terms of the Securities Purchase Agreement will remain unchanged. Both companies are working to complete the transaction by December 25, 2020. The announcement includes a legal notice regarding forward-looking statements and the associated risks and uncertainties. IDAD does not anticipate any updates to the forward-looking statement. Neither IDAD nor IR MED are subject to the reporting requirements of the Securities and Exchange Commission.
Acquisition
growth-positive
International Display Advertising, Inc and ir Med Ltd Agree to Securities Exchange Agreement
IDAD has entered into a Securities Exchange Agreement with IR Med Ltd., an Israeli company, to acquire IR Med as a wholly owned subsidiary. The shareholders of IR Med will receive 31,043,945 shares of common stock of IDAD. The transaction is subject to closing conditions, including obtaining a tax ruling from the Israeli tax authorities and a private placement with net proceeds of $1.8 million to $5 million. The merged entity will focus on further development and commercialization of medical devices. IDAD intends to change its corporate name to IR Med Inc. and obtain a new trading symbol. The CEO of IDAD expressed excitement about the merger, while the founder of IR Med believes it will result in significant growth for the post-merger company.
AcquisitionInvestment
growth-positive
International Display Advertising, Inc. Announces Letter of Intent to Merge with IR Med Ltd.
IDAD has entered into a non-binding letter of intent to merge with IR Med, Ltd., a medical device company. After the merger, IR MED shareholders will own between 43% and 59% of IDAD. The merger is subject to closing conditions and a private placement of securities by IDAD. The combined company plans to focus on revenue growth, R&D investment, sales and marketing initiatives, and strategic acquisitions. IDAD has also completed a reverse stock split. The article includes a legal notice regarding forward-looking statements.
AcquisitionManagement Changes
IR-MED Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 11 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
IR-MED Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 99/100 |
| Missing | markets |
| BI Verification | RPA |
| Registrar ID | 514824952 |
| Crunchbase | ir-med |
| Phone | +97246555054 |
| Creator | Ronnie Klein |
| Creator email | ronnie@pimsmed.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-11-13T00:00:00.000Z |
| Created | 2017-08-25T00:00:00.000Z |
| Status detail | Public on OTCQB on Dec, 2020; |